These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 27689729)
1. Natural and synthetic bioactive inhibitors of glycogen synthase kinase. Khan I; Tantray MA; Alam MS; Hamid H Eur J Med Chem; 2017 Jan; 125():464-477. PubMed ID: 27689729 [TBL] [Abstract][Full Text] [Related]
2. Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions. Saraswati AP; Ali Hussaini SM; Krishna NH; Babu BN; Kamal A Eur J Med Chem; 2018 Jan; 144():843-858. PubMed ID: 29306837 [TBL] [Abstract][Full Text] [Related]
3. Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease. Maqbool M; Mobashir M; Hoda N Eur J Med Chem; 2016 Jan; 107():63-81. PubMed ID: 26562543 [TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Martinez A; Castro A; Dorronsoro I; Alonso M Med Res Rev; 2002 Jul; 22(4):373-84. PubMed ID: 12111750 [TBL] [Abstract][Full Text] [Related]
5. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. Martinez A Med Res Rev; 2008 Sep; 28(5):773-96. PubMed ID: 18271054 [TBL] [Abstract][Full Text] [Related]
6. Glycogen synthase kinases: Moonlighting proteins with theranostic potential in cancer. Nagini S; Sophia J; Mishra R Semin Cancer Biol; 2019 Jun; 56():25-36. PubMed ID: 29309927 [TBL] [Abstract][Full Text] [Related]
7. [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors]. Liu SN; Shen ZF Yao Xue Xue Bao; 2007 Dec; 42(12):1227-31. PubMed ID: 18338632 [TBL] [Abstract][Full Text] [Related]
14. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors. Avila J; Wandosell F; Hernández F Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491 [TBL] [Abstract][Full Text] [Related]
15. The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases. Amar S; Belmaker RH; Agam G Curr Pharm Des; 2011; 17(22):2264-77. PubMed ID: 21736545 [TBL] [Abstract][Full Text] [Related]
17. Discovery of Isonicotinamides as Highly Selective, Brain Penetrable, and Orally Active Glycogen Synthase Kinase-3 Inhibitors. Luo G; Chen L; Burton CR; Xiao H; Sivaprakasam P; Krause CM; Cao Y; Liu N; Lippy J; Clarke WJ; Snow K; Raybon J; Arora V; Pokross M; Kish K; Lewis HA; Langley DR; Macor JE; Dubowchik GM J Med Chem; 2016 Feb; 59(3):1041-51. PubMed ID: 26751161 [TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase kinase-3 as drug target: from wallflower to center of attention. Van Wauwe J; Haefner B Drug News Perspect; 2003 Nov; 16(9):557-65. PubMed ID: 14702136 [TBL] [Abstract][Full Text] [Related]
19. Andrographolide activates the canonical Wnt signalling pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-3β: autoregulation of GSK-3β in vivo. Tapia-Rojas C; Schüller A; Lindsay CB; Ureta RC; Mejías-Reyes C; Hancke J; Melo F; Inestrosa NC Biochem J; 2015 Mar; 466(2):415-30. PubMed ID: 25423492 [TBL] [Abstract][Full Text] [Related]